These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 6781763)
1. The blocking activity of antisera raised to either tumor antigens or alloantigens in cytotoxicity assays using syngeneic or allogeneic killer cells on the P815 murine mastocytoma target. Al-Rammahy AK; Levy JG Cell Immunol; 1980 Dec; 56(2):338-46. PubMed ID: 6781763 [No Abstract] [Full Text] [Related]
2. Preparation and properties of antisera directed against antigens of the P-815 mastocytoma cell not shared by its syngeneic host, the DBA/2 mouse. Bertschmann M; Clemetson KJ; Lüscher EF Eur J Cancer (1965); 1976 Apr; 12(4):255-62. PubMed ID: 60238 [No Abstract] [Full Text] [Related]
3. Modulation of natural cytotoxicity by alloantibodies. I. Alloantisera enhancement of cytotoxicity of mouse spleen cells toward a human myeloid cell line. Saxena RK; Adler WH J Immunol; 1979 Aug; 123(2):846-51. PubMed ID: 110883 [TBL] [Abstract][Full Text] [Related]
4. Modulation of natural cytotoxicity by alloantibodies. V. The mechanism of a selective augmenting effect of anti-H-2 antisera on the natural killer activity of mouse spleen cells. Saxena RK; Saxena QB; Adler WH Cell Immunol; 1981 Nov; 65(1):115-30. PubMed ID: 6797740 [No Abstract] [Full Text] [Related]
5. Solubilization of histocompatibility and tumour-associated antigens of the P-815 murine mastocytoma cell. Clemetson KJ; Gerber A; Bertschmann M; Lüscher EF Eur J Cancer (1965); 1976 Apr; 12(4):263-70. PubMed ID: 821757 [No Abstract] [Full Text] [Related]
6. The Lyt phenotype of cells involved in the cytotoxic response to syngeneic tumor and of tumor-specific suppressor cells. Maier T; Levy JG; Kilburn DG Cell Immunol; 1980 Dec; 56(2):392-9. PubMed ID: 6451300 [No Abstract] [Full Text] [Related]
7. Lysis of enucleated tumor cells with allogeneic and syngeneic cytotoxic thymus-derived lymphocytes. Hale AH; Paulus LK Eur J Immunol; 1979 Aug; 9(8):640-6. PubMed ID: 227696 [No Abstract] [Full Text] [Related]
8. Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens. Romani L; Grohmann U; Fazioli F; Puccetti P; Mage MG; Fioretti MC Cancer Immunol Immunother; 1988; 26(1):48-54. PubMed ID: 3257903 [TBL] [Abstract][Full Text] [Related]
9. Analysis of antibody production induced by allogeneic tumor cells inoculated into the anterior chamber of the eye. Niederkorn JY; Streilein JW Transplantation; 1982 Jun; 33(6):573-7. PubMed ID: 6808721 [TBL] [Abstract][Full Text] [Related]
10. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells. Sensi ML; Parenza M; Parmiani G J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938 [TBL] [Abstract][Full Text] [Related]
11. Isolation and partial characterization of a tumor-associated antigen of the P815 mastocytoma of DBA/2 mice. Al-Rammahy AK; Levy JG; Jackson AL J Immunol; 1980 Jan; 124(1):143-50. PubMed ID: 6765966 [No Abstract] [Full Text] [Related]
12. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma. Prell RA; Kerkvliet NI J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803 [TBL] [Abstract][Full Text] [Related]
13. Murine macrophage cytotoxicity induced by mastocytoma cells, cell-free mastocytoma exudates, and extracts. Dullens HF; Den Otter W Immunopharmacology; 1981 Sep; 3(3):241-51. PubMed ID: 6796544 [TBL] [Abstract][Full Text] [Related]
14. Antigenic changes of DBA/2J mastocytoma cells when grown in the BALB/c mouse. Wolf JE; Faanes RB; Choi YS J Natl Cancer Inst; 1977 May; 58(5):1407-12. PubMed ID: 67213 [TBL] [Abstract][Full Text] [Related]
15. Degradation of specificity in cytolytic T lymphocyte clones: two broad specificity, H-2-independent recognition systems, one natural killer-like, develop during culture, in addition to the clonally distributed antigen-specific receptor. Wilson A; Shortman K Eur J Immunol; 1985 Sep; 15(9):899-905. PubMed ID: 2412835 [TBL] [Abstract][Full Text] [Related]
16. Augmentation of killer activity of murine spleen cells against allogeneic and syngeneic tumor cells by inoculation of alloantigen in vivo. Nishi Y; Hosokawa T; Aoike A; Kamahora T; Sudo H; Kawai K Microbiol Immunol; 1987; 31(12):1245-54. PubMed ID: 2453782 [TBL] [Abstract][Full Text] [Related]
17. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies. Carayanniotis G; Halloran PF Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596 [TBL] [Abstract][Full Text] [Related]
18. Discussion paper: the immune status of the murine host bearing transplantable syngeneic growing tumors. Manson LA Ann N Y Acad Sci; 1976; 276():272-5. PubMed ID: 829206 [No Abstract] [Full Text] [Related]
19. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. Maryanski JL; Boon T Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608 [TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects of an antiserum raised in syngeneic mice to a tumor-specific T suppressor factor. Maier T; Levy JG Cancer Immunol Immunother; 1982; 13(2):134-9. PubMed ID: 6819080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]